Fieldview Capital Management LLC Takes $495,000 Position in Edwards Lifesciences Corporation $EW

Fieldview Capital Management LLC purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,808 shares of the medical research company’s stock, valued at approximately $495,000.

Other large investors have also modified their holdings of the company. Washington Trust Advisors Inc. raised its holdings in shares of Edwards Lifesciences by 15.6% in the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after purchasing an additional 17,625 shares in the last quarter. Elo Mutual Pension Insurance Co raised its holdings in shares of Edwards Lifesciences by 39.9% in the 3rd quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after purchasing an additional 25,562 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after purchasing an additional 23,514 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Edwards Lifesciences by 39.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after purchasing an additional 648,870 shares in the last quarter. Finally, Central Pacific Bank Trust Division bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $775,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Monday, April 13th. Barclays reiterated an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. BTIG Research boosted their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $95.96.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 81,038 shares of company stock worth $6,683,255 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 1.4%

NYSE EW opened at $86.27 on Tuesday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a market cap of $49.68 billion, a PE ratio of 45.89, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87. The company has a 50 day moving average price of $82.88 and a 200 day moving average price of $83.10. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $89.48.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.